Low Frequency Ultrasonication Induced Antitumor Effect in 5-Aminolevulinic Acid Treated Malignant Glioma

Fumio Yamaguchi¹*, Takayuki Asakura¹, Hiroshi Takahashi¹,², Takayuki Kitamura¹, Akira Teramoto¹,³

¹Department of Neurosurgery, Nippon Medical School, Tokyo, Japan; ²Department of Neurosurgery, Kasugai Rehabilitation Hospital, Yamanashi, Japan; ³Tokyo Rosai Hospital, Tokyo, Japan.

Email: *fyamaguc@nms.ac.jp

Received January 2nd, 2013; revised February 1st, 2013; accepted February 9th, 2013

ABSTRACT

We investigated the feasibility of sonodynamic therapy for glioma by low frequency ultrasound with 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) in heme synthetic process. In vivo tumor model was made by inoculating human glioma cell line U87-MG subcutaneously in nude mice. The tumor was sonicated by 25-kHz ultrasound 4 hours following administration of 5-ALA. The tumor size decreased in 5-ALA administered (ALA(+US(+)) mice, while increased in non-5-ALA administrated (ALA(−)US(−)) mice and non-sonicated mice (ALA(+)US(−)). The immunohistochemical analysis revealed an apoptotic change in tumor tissue of ALA(+)US(+) mice. The results showed the therapeutic effect of 25 kHz ultrasound for the glioma in 5-ALA administered tumor-bearing mice by inducing apoptotic change of tumor cells. This is a first report to elucidate the feasibility of therapeutic use of 25 kHz, relatively low frequency, ultrasound in sonodynamic therapy using 5-ALA as a sonosensitizer precursor. The utilization of this frequency will contribute to the development of sonodynamic therapy for gliomas and the spread of this technique in many hospitals that possess ultrasonic aspirators.

Keywords: Glioma; Sonodynamic Therapy; 5-Aminolevulinic Acid; Protoporphyrin IX; Ultrasonication

1. Introduction

Glioma has an invasive nature and often invades into the proximity of critically functioning structures. Gross total resection, even though it is a standard therapy, often results in postoperative neurological deteriorations. To avoid this sequel, photodynamic therapy is a promising technique to kill tumor tissue selectively near the functioning brain tissue. Although photodynamic therapies have been investigated and reported to be effective therapies for a wide variety of cancers [1], this technique failed to kill glioma cells locating deep in the brain because of low penetration of light in the brain tissue.

Ultrasound, which has a property of conducting into deep tissues, activates sonosensitizers and induces their cytotoxic effects. Protoporphyrin IX (PpIX), metabolic product of 5-aminolevulinic acid (5-ALA), is known as a sonododynamically activated sensitizer as well as a photosensitizer [2-4]. Because 5-ALA has been widely used for photo diagnosis to confirm the existence of residual tumor tissue during brain tumor resection [5], 5-ALA-derived PpIX seems a good candidate as a safe sonosensitizer in brain tumors. Also PpIX has a property of tumor-specific accumulation [6]. Therefore it is important to know whether sonodynamic therapy (SDT) in combination with 5-ALA shows significant in vivo antitumor effects in gliomas. In most studies, the ultrasound frequency above 1 MHz is used in sonodynamic therapy to activate sonosensitizers [7,8]. In this study we investigated the feasibility of sonodynamic therapy with relatively low frequency ultrasound of 25kHz which is often used in ultrasonic surgical aspirators [9,10]. This is a first report on the utilization of low-frequency ultrasound for sonodynamic therapy of human glioma. And the utilization of this frequency will contribute to the development of sonodynamic therapy for gliomas and the spread of this technique in many hospitals that possess ultrasonic aspirators.

2. Materials and Methods

2.1. Chemical

5-aminolevulinic acid (Cosmo BioCo., Ltd., Tokyo, Japan) was dissolved in 1N HCl solution and 100 mM stock solution was sterilized, aliquoted and stored in the
dark at −20°C.

2.2. Glioma Cell Line

U87MG is a well-characterized human glioblastoma cell line [11]. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Life Technologies, Inc., USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, USA), 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO₂ atmosphere. Cells in the exponential phase of growth were used in each experiment.

2.3. Ultrasonic Generator

The ultrasound transducer was manufactured by TOKYO IKEN CO., LTD (Tokyo, Japan). Its ultrasonic electronic generator generates a 25 kHz signal, which is converted by the transducer to a mechanical vibration of the internal piezoelectric crystals. An ultrasound transducer with a diameter of 10 mm was used with a resonant frequency of 25 kHz. The vibration is amplified and transmitted down the length of the probe where the tip longitudinally expands and contracts. The distance the tip travels is dependent on the amplitude. To specify the intensity in the insonation experiment, the reading power (μm) of generator was used which represented the amplitude of vibrating width of the tip of transducer.

2.4. Animals

The virgin female nu/nu BALB/c mice (5 weeks old; 19 ± 2 g) used in these experiments were obtained from Charles River Laboratories Japan, INC. Mice were housed in micro isolation in a dedicated, pathogen-free facility, and all animal experimentation was conducted in accordance with the declaration of Helsinki or the Guide for the Care and Use of Experimental Animals of Nippon Medical School.

2.5. In Vivo Tumor Model

Twenty one mice were subcutaneously inoculated with U87-MG tumor cells (1 × 10⁷ cells/mouse, respectively) in the right legs. All tumors reached to the target volume by approximately four weeks after inoculation.

2.6. Treatment in Nude Mice

The 20 tumor-bearing mice were randomly divided into four groups: control group (ALA(−)US(−)), ALA only group (ALA(+)US(−)), sonication only group (ALA(+)US(+)), and ALA plus sonication group (ALA(+)US(+) group). Each group had five mice. 5-ALA was administered to the mice of ALA(+)US(−) and ALA(+)US(+) groups at a dose of 100 mg/kg via transgastric route.

2.7. Confirmation of Protoporphyrin IX Expression

The surface of the subcutaneous tumors were exposed by skin opening and irradiated by 405 nm blue Lasers generated by diode Lasers apparatus manufactured for experimental use by IHI Corporation (Tokyo, Japan). Protoporphyrin IX expression was confirmed by the observation of emitting red light.

2.8. Ultrasound Exposure

Animals were anesthetized with 50 mg/kg ketamine and 10 mg/kg xylazine after four-hour incubation with 5-ALA. An acoustically transparent gel was applied on the skin over the subcutaneous tumor. An ultrasound transducer with a diameter of 10 mm was horizontally attached on the surface of skin over subcutaneous tumor. The tumors were sonicated using ultrasound of 25 kHz at an intensity of 4 μm for 4 minutes individually for five mice of ALA(+)US(+) group and five mice of ALA(+)US(−) group. Five mice of ALA(−)US(−) and five mice of ALA(+)US(−) groups were not sonicated. These experiments were conducted at one sonication condition based on the experiments showing it was the most efficient conditions for in vivo sonodynamic treatment with this apparatus. All experiments were conducted at 20°C under a dim light condition.

2.9. Tumor Growth Analysis

Tumor sizes were measured with calipers for each individual mouse once a week, and the tumor volume (mm³) was calculated as (L × W × H)/2, where L = length (mm), W = width (mm) and H = height (mm). Growth rates were calculated; Tumor growth rate = tumor volume (mm³) of each time point /tumor volume (mm³) at the sonication, and plotted (±Standard error of mean: SE).

2.10. Statistical Analysis

Mann-Whitney’s U test was performed to determine differences of tumor growth rate between treatment groups. A P value of <0.05 was considered significant.

2.11. Histological Analysis and Evaluation of Apoptosis

One tumor-bearing mouse was prepared to analyze the histological change after ultrasonic treatment. Subcutaneous tumor was treated by ultrasonication under the same experimental condition as ALA(+) group, but when the tumor size reached at the approximately 15 mm in diameter. One week after treatment, a mouse was sacrificed by cervical dislocation and the tumors were removed. A tumor sample was fixed in 10% formaldehyde
for 6 hours and paraffin embedded. Thin sections of 5 microns were stained with hematoxylin-eosin (H&E). Tissue section was also treated using ApopTag® (Millipore, MA, USA) for the detection of fragmented genomic DNA. Briefly, paraffin sections were dewaxed and rehydrated, treated with proteinase K (20 μg/ml) for 15 min and washed in PBS. Endogenous peroxidase was blocked with 3% H2O2 for 15 min. Slides were then covered with equilibration buffer and were incubated for 1 min at 37°C. This was followed by the incubation with the TdT for 60 min at 37°C. The reaction then was terminated using the ApopTag® stop buffer followed by anti-digoxigenin-peroxidase application. Fluorescence was viewed by fluorescence microscopy using standard fluorescein excitation and emission long pass filters for FITC.

3. Results

3.1. SDT Induced Suppression of Tumor Growth

In vivo, the size of tumors decreased in the ALA(+)US(+) mice, while that of ALA(−)US(−), ALA(−)US(+) and ALA(+)US(−) group showed the continuous growth of tumors. In Figure 1, representative animals of ALA(+)US(+) group and ALA(−)US(+) group were shown. The subcutaneous tumor was rapidly shrinking and diminished by Day21. Tumors volumes of 5-ALA plus sonication group (ALA(+)US(+)) decreased after transdermal sonication, while tumors of non-5-ALA group (ALA(−)US(+)) were continuously growing (Figure 2). The mean of tumor growth rate of ALA(+)US(+) group was 0.08 ± 0.08 (mean ± SE), while the other groups showed high growth rate; ALA(−)US(−): 6.89 ± 1.19, ALA(+)US(−): 4.85 ± 1.69, and ALA(−)US(+) 5.08 ± 2.77 (Figure 2).

![Figure 1. Subcutaneous tumors. Tumors volumes of 5-ALA plus sonication group (ALA(+)US(+)) decreased after transdermal sonication, while tumors of non-5-ALA group (ALA(−)US(−)) were continuously growing. (Representative cases shown).](image1)

![Figure 2. Growth rate of implanted tumors. The tumor growth rate of ALA(+)US(+) group showed significant decrease after sonication, while no decrease in ALA(−)US(−), ALA(−)US(+) and ALA(+)US(−) group. (SE: standard error of mean).](image2)
The decrease of the growth rate of ALA(+)/US(+) group is statistically significant at 21 days after sonication compared with the other groups; ALA(−)/US(+) (p = 0.0214), ALA(+)US(−) (p = 0.0121) and ALA(−)/US(−) (p = 0.0121).

Since the growth rate at Day21 of ALA(−)/US(+) group was not different from that of ALA(−)/US(−) group (p = 0.529), ultrasonication itself did not show suppressive effect on tumor growth. Also the growth rates of ALA(+)US(−) and ALA(−)/US(−) group were not different (p = 0.095), 5-aminolevulinic acid was not harmful on tumor at this dose.

3.2. SDT Induced Apoptosis of Tumor

H&E staining revealed that treatment by sonication mediated significant apoptosis in U87MG glioma in vivo (Figures 3(A) and (B)). A broad zone of a nuclear and a cellular eosinophilic debris, ringed by a zone of tumor cells in the process of undergoing apoptosis, was evident in the ALA(+)US(+) group but not the other groups. Damaged tumor by this therapy showed the vast apoptosis component to a depth of approximately 1 cm (Figures 3(C) and (D)), while no apoptotic change was seen in tumor tissue where sonication was not applied.

4. Discussion

4.1. Antitumor Effect

Sonodynamic therapy is an approach based on the synergistic effect of ultrasound and chemical compound referred to as “sonosensitizer” for cancer treatment. Several studies have been conducted in vitro and in vivo to investigate the cytotoxic effect of the combination of ultrasounds and hematoporphyrin, the most common photodynamic sensitizer, showing encouraging results [12-14]. Recently the in vivo effect of the combination of PpIX and ultrasound exposure on a subcutaneously implanted sarcoma 180 (S180) solid tumor was investigated with ultrasound at a frequency of 2.2 MHz [15]. However, the sonodynamic effect of PpIX on glioma has not been studied in details so far, moreover low frequency as 25 kHz instead of high frequency as 2 MHz is not studied.

Our experiment showed that the increase of tumor volume was remarkably inhibited with combination of 5-ALA and ultrasound. Since the growth rate at Day21 of ALA(−)/US(+) group was not different from that of ALA(−)/US(−) group, sonication itself did not show any tumor suppressive effect. 5-aminolevulinic acid was also not harmful on tumor at this dose because the growth rates of ALA(+)US(−) and ALA(−)/US(−) group were not statistically different. Therefore tumor suppression may be induced by the synergistic effects of 5-ALA and ultrasound. Since the sonication immediate after administration of 5-ALA did not show any tumor suppressive effect, 5-ALA-derived chemicals, instead 5-ALA itself, may have worked for cytotoxicity. PpIX is one of metabolites of 5-ALA known as a photosensitizer and also a sonosensitizer. The production of PpIX was confirmed by red color photic excitation at the time of sonication, so that PpIX may be the most probable chemical working as a sonosensitizer in our study.

4.2. The Mechanism of SDT

Microscopic observation found that the cell ultra-structure was significantly damaged, and apoptotic change of tumor cells remarkably increased after sonodynamic treatment. Recently Song et al. [7] reported that sonodynamic therapy using 5-aminolevulinic acid induced the apoptotic change of SAS human tongue squamous cell carcinoma cells. Also Li et al. [16] also reported the detail tumor cell change that caspase-depended apoptosis could be induced by PpIX-SDT in human breast cancer MDA-MB-231 cells, and the intracellular reactive oxygen species were involved during the apoptotic process. In these reports, 1.05 MHz ultrasound was used which is a popular ultrasound frequency for sonodynamic therapies. Considering the result of our experiment in which the frequency of 25 kHz used, this apoptotic change occurs not only by high frequencies but also by low frequencies around 25 kHz.

4.3. Potential Clinical Application

Photodiagnosis (PD) using 5-ALA has been one of the
popular methods to confirm the existence of tumor tissue during the removal or the biopsy of brain tumors [5]. 5-ALA is known as a safe and reliable chemical used clinically in glioma patients and our data showed that it is working in synergy with ultrasound inducing apoptotic change of glioma cells. This method is a promising therapy on the unresectable tumors.

The frequency that we used is the vibration frequency of ultrasonic surgical aspirator which is often used in brain tumor surgeries. If this frequency can be used for sonodynamic therapy for glioma, it seems feasible to use the ultrasonic surgical aspirator with minimal change such as an exchange of hand piece. Even though this technique is a promising therapy, its clinical applications are still under debate since the specific mechanisms of sonosensitization are influenced by multiple factors, including the nature of the biological model, the sonosensitizer and the ultrasound parameters.

The optimal conditions to obtain stable antitumor effect should be elucidated before application of this method to clinical cases.

In summary, Low-frequency sonochemical therapy utilizing 5-ALA reduced the volume of malignant gliomas. The mechanism was suggested to be the induction of apoptosis in glioma cells. This therapy may become an alternative treatment for unresectable invaded tumors in patients in whom gross total resection is considered to result in unacceptable sequel. Further analyses are necessary to conclude that this sonodynamic therapy can be clinically applied to glioma therapy.

5. Acknowledgement

This work was supported in part by a grant of Strategic Research Foundation Grant-aided Project for Private Universities from Ministry of Education, Culture, Sport, Science, and Technology, Japan (MEXT) (S0801035).

Technological supports on ultrasonic device were provided by TOKYO IKEN CO., LTD (Tokyo, Japan)

We are grateful to Mr. Katsuichi Inoue, (SBI PharmaceuticaLS Co., Ltd., Tokyo, Japan) for his technical support on Lasers apparatus.

REFERENCES


**Abbreviations**

5-ALA, 5-aminolevulinic acid;
PpIX, protoporphyrin IX;
SDT, sonodynamic therapy